Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

56.73 +0.86 (+1.53%)
Streaming Delayed Price Updated: 2:20 PM EDT, Jul 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,459,005
Open 56.32
Bid (Size) 56.70 (200)
Ask (Size) 56.75 (200)
Prev. Close 55.87
Today's Range 56.19 - 57.36
52wk Range 40.03 - 86.74
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Cathie Wood Just Bet Big on This Biotech Stock ↗
Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing? 
Via The Motley Fool
Topics ETFs

Performance

YTD
-28.8%
-28.8%
1 Month
-25.4%
-25.4%
3 Month
-23.4%
-23.4%
6 Month
-30.6%
-30.6%
1 Year
+33.8%
+33.8%

More News

Read More
News headline image
Ionis to hold second quarter 2026 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Via MarketBeat
News headline image
IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Via InvestorPlace
News headline image
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts ↗
Via MarketBeat
News headline image
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference ↗
Via MarketBeat
News headline image
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to host 2026 virtual Annual Meeting of Stockholders
From Ionis Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 56.73
When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 07/24/26 02:20 PM ET
What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 8.04B
How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
Ionis Pharmaceuticals, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.